Chat with us in Facebook Messenger. Find out what's happening in the world as it unfolds.

FILE - In this Friday, Sept. 27, 2013, file photo, a tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals in the company's Raleigh, N.C., headquarters. Sprout Pharmaceuticals, the makers of the twice-rejected pill intended to boost libido in women, will make a third attempt this week at convincing regulators to approve the drug as the first prescription treatment for low sexual desire in women. A panel of FDA experts will discuss the drug at a public meeting Thursday, June 4, 2015 before voting on whether to recommend its approval.(AP Photo/Allen G. Breed, File)
FILE - In this Friday, Sept. 27, 2013, file photo, a tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals in the company's Raleigh, N.C., headquarters. Sprout Pharmaceuticals, the makers of the twice-rejected pill intended to boost libido in women, will make a third attempt this week at convincing regulators to approve the drug as the first prescription treatment for low sexual desire in women. A panel of FDA experts will discuss the drug at a public meeting Thursday, June 4, 2015 before voting on whether to recommend its approval.(AP Photo/Allen G. Breed, File)

    JUST WATCHED

    Women testify: We need "Viagra" just as much as men

MUST WATCH

Women testify: We need "Viagra" just as much as men

Amanda Parrish was a part of the clinical trials for Flibanserin, a new libido drug that is close to FDA approval. She & husband Ben share their experience.

Women testify: We need "Viagra" just as much as men

Amanda Parrish was a part of the clinical trials for Flibanserin, a new libido drug that is close to FDA approval. She & husband Ben share their experience.